Overview

An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients

Status:
Completed

Trial end date:
2016-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the effects of CPX-351 on cardiac repolarization, assess plasma drug levels, asses serum copper levels, and assess drug levels in urine. Efficacy and Safety will be assessed in all patients enrolled to the study.

Phase:

Phase 2

Details

Lead Sponsor:

Celator Pharmaceuticals
Jazz Pharmaceuticals

Treatments:

Cytarabine
Daunorubicin